Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Dendritic Cells Induce Specific Cytotoxic T Lymphocytes against Prostate Cancer TRAMP-C2 Cells Loaded with Freeze-thaw Antigen and PEP-3 Peptide

  • Liu, Xiao-Qi (Molecular Medicine and Cancer Research Center, Department of Biochemistry and Molecular Biology, Chongqing Medical University) ;
  • Jiang, Rong (Department of Stem Cell and Tissue Engineering, Chongqing Medical University) ;
  • Li, Si-Qi (Molecular Medicine and Cancer Research Center, Department of Biochemistry and Molecular Biology, Chongqing Medical University) ;
  • Wang, Jing (Molecular Medicine and Cancer Research Center, Department of Biochemistry and Molecular Biology, Chongqing Medical University) ;
  • Yi, Fa-Ping (Molecular Medicine and Cancer Research Center, Department of Biochemistry and Molecular Biology, Chongqing Medical University)
  • Published : 2015.02.25
Download PDF
⟨ Previous Next ⟩

Abstract

Prostate cancer is the most common cancer in men. In this study, we investigated immune responses of cytotoxic T lymphocytes (CTLs) against TRAMP-C2 prostate cancer cells after activation by dendritic cells (DCs) loaded with TRAMP-C2 freeze-thaw antigen and/or PEP-3 peptide in vitro. Bone marrow-derived DC from the bone marrow of the C57BL/6 were induced to mature by using the cytokine of rhGM-CSF and rhIL-4, and loaded with either the freeze-thaw antigen or PEP-3 peptide or both of them. Maturation of DCs was detected by flow cytometry. The killing efficiency of the CTLs on TRAMP-C2 cells were detected by flow cytometry, CCK8, colony formation, transwell migration, and wound-healing assay. The levels of the IFN-${\gamma}$, TNF-${\beta}$ and IL-12 were measured by enzyme-linked immunosorbent assay (ELISA). Compared with the unloaded DCs, the loaded DCs had significantly increased expression of several phenotypes related to DC maturation. CTLs activated by DCs loaded with freeze-thaw antigen and PEP-3 peptide had more evident cytotoxicity against TRAMP-C2 cells in vitro. The secretion levels of IFN-${\gamma}$, TNF-${\beta}$ and IL-12, secreted by DCs loaded with antigen and PEP-3 and interaction with T cells, were higher than in the other groups. Our results suggest that the CTLs activated by DCs loaded with TRAMP-C2 freeze-thaw antigen and PEP-3 peptide exert a remarkable killing efficiency against TRAMP-C2 cells in vitro.

Keywords

References

  1. Bolhassani A, Safaiyan S, Rafati S (2011). Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer, 10, 3.
  2. Chiang CL, Benencia F, Coukos G (2010). Whole tumor antigen vaccines. Semin Immunol, 22, 132-43. https://doi.org/10.1016/j.smim.2010.02.004
  3. Chiang CL, Hagemann AR, Leskowitz R, et al (2011). Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses. PLoS One, 6, 28732. https://doi.org/10.1371/journal.pone.0028732
  4. Clive KS, Tyler JA, Clifton GT, et al (2012). The GP2 peptide: A HER2/neu-based breast cancer vaccine. J Surg Oncol, 105, 452-8. https://doi.org/10.1002/jso.21723
  5. Drake CG (2010). Prostate cancer as a model for tumor immunotherapy. Nat Rev Immunol, 10, 580-93. https://doi.org/10.1038/nri2817
  6. Furnari FB, Huang HJ, Cavenee WK (1996). Molecular biology of malignant degeneration of astrocytoma. Pediatr Neurosurg, 24, 41-9. https://doi.org/10.1159/000121013
  7. Guo K, Liu CX (2010). Research progress on the serum markers of prostate cancer. J Practical Med, 26, 3465-6.
  8. Gilboa E, Nair SK, Lyerly HK (1998). Immunotherapy of cancer with dendritic-cell-based vaccines. Immunother, 46, 82-7. https://doi.org/10.1007/s002620050465
  9. Hong Ge, Xiaoqi Gong, Careen K (2002). Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer, 98, 357-61. https://doi.org/10.1002/ijc.10224
  10. Heimberger AB, Crotty LE, Archer GE, et al (2003). Epidermal growth factor receptor variant VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res, 11, 4247-54.
  11. Inaba K, Inaba M, Romani N, et al (1992). Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colonystimulating factor. J Exp Med, 176, 1693-702. https://doi.org/10.1084/jem.176.6.1693
  12. Jacques Ferlay, Hai-Rim Shin, Freddie Bray, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  13. Kreiter S, Diken M, Selmi A, et al (2011). Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol, 23, 399-406. https://doi.org/10.1016/j.coi.2011.03.007
  14. Kang TH, Mao CP, La V, Chen A, et al (2013). Innovative DNA vaccine to break immune tolerance against tumor self-antigen. Hum Gene Ther, 24, 181-8. https://doi.org/10.1089/hum.2012.141
  15. Lee HJ, Hong CY, Kim MH, et al (2012). In vitro induction of anterior gradient-2-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses as a potential therapy for colorectal cancer. Exp Mol Med, 44, 60-7. https://doi.org/10.3858/emm.2012.44.1.006
  16. Lorenzi S, Mattei F, Sistigu A, et al (2011). Type I IFNs control antigen retention and survival of CD8a (+) dendritic cells after uptake of tumor apoptotic cells leading tocrosspriming. J Immunol, 186, 5142-50. https://doi.org/10.4049/jimmunol.1004163
  17. Long JR, Xiong F, Dong ZQ (2010). Research progress on multiple drug resistance of prostate cancer. Guangdong Med J, 31, 2871-3.
  18. McDonnell AM, Prosser AC, Van Bruggen I, et al (2010). CD8alpha+DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor. Eur J Immunol, 40, 1617-27. https://doi.org/10.1002/eji.200940153
  19. Matera L (2011). The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer. Cancer Treat Rev, 36, 131-41.
  20. Morandi F, Chiesa S, Bocca P, et al (2006). Tumor mRNAtransfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications. Neoplasia, 10, 833-42.
  21. Park MH, Yang DH, Kim MH, et al (2011). Alpha-Type 1 polarized dendritic cells loaded with apoptotic allogeneic breast cancer cells can induce potent cytotoxic T lymphocytes against breast cancer. Cancer Res Treat, 43, 56-66. https://doi.org/10.4143/crt.2011.43.1.56
  22. Quintarelli C, Dotti G, Hasan ST, et al (2011). High-avidity cytotoxic-T-lymphocytes specific for a new preferentially expressed antigen of melanoma (PRAME)-derived peptide can target leukemic- and leukemic-precursor cells. Blood, 117, 3353-62. https://doi.org/10.1182/blood-2010-08-300376
  23. Roupret M, Zigeuner R, Palou J, et al (2011). European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol, 59, 584-94. https://doi.org/10.1016/j.eururo.2010.12.042
  24. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
  25. Stockwin LH, McGonagle D, Martin IG, et al (2000). Dendritic cells immunological sentinels with a central role in health and disease. Immunol Cell Biol, 78, 91-102. https://doi.org/10.1046/j.1440-1711.2000.00888.x
  26. Timothy R, Susan S, Bao-Li Chang, et al (2013). Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of African descent. Prostate Cancer, 2013, 1-12.
  27. Tel J, Schreibelt G, Sittig SP, et al (2013). Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood, 121, 459-67. https://doi.org/10.1182/blood-2012-06-435644
  28. Yi XM, Zhou WQ (2010). Epigenetics of prostate cancer. National J Androl, 16, 635-41.
  29. Yiin JJ, Hu B, Schornack PA, Sengar RS, et al (2010). ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain. Mol Cancer Ther, 9, 929-41. https://doi.org/10.1158/1535-7163.MCT-09-0953
  30. Yang DH, Kim MH, Hong CY, et al (2010). Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells. Ann Hematol, 89, 795-801. https://doi.org/10.1007/s00277-010-0931-3